A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

por Ramasamy, Karthik, Nooka, Ajay, Quach, Hang, Htut, Myo, Popat, Rakesh, Liedtke, Michaela, Tuchman, Sascha A., Laubach, Jacob, Gasparetto, Cristina, Chanan-Khan, Asher, Hertzberg, Mark, deMario, Mark, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Cho, Hearn Jay
Publicado 2021

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

por Shapiro, Geoffrey I., LoRusso, Patricia, Dowlati, Afshin, T. Do, Khanh, Jacobson, Caron A., Vaishampayan, Ulka, Weise, Amy, Caimi, Paolo F., Eder, Joseph Paul, French, Christopher A., Labriola-Tompkins, Emily, Boisserie, Frédéric, Pierceall, William E., Zhi, Jianguo, Passe, Sharon, DeMario, Mark, Kornacker, Martin, Armand, Philippe
Publicado 2020

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

por Dickinson, Michael, Briones, Javier, Herrera, Alex F., González-Barca, Eva, Ghosh, Nilanjan, Cordoba, Raul, Rutherford, Sarah C., Bournazou, Eirini, Labriola-Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, DeMario, Mark, Rüttinger, Dominik, Kornacker, Martin, Hutchings, Martin
Publicado 2021